Since using 12.5–50 μM of RSV is clinically achievable based on aforementioned in vivo studies [43–49], the RSV induced upregulation of Rad9 in human breast and lung cancer cells could represent a potential novel therapy for breast and lung cancers. Here, RAD9A is linked to lung cancer.